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Abstract 
4,4’-Diisothiocyanato-stilbene-2,2’-dlsulfonic acid (DIDS) stimulates human platelets via cc ,,-adrenerglc receptor-mediated activation of protein 
kmase C (PKC) independent of the phospholipase C pathway. Here we show, that in permeabilized platelets activation of PKC by DIDS (20 PM), 
measured as “P incorporation in pleckstrin, is completely inhibited by guanosine 5’-(2-0-thio)diphosphate (200 fiM), an inhibitor of heterotrimeric 
G-proteins. Also pertussin toxin (4 ,&ml), which ADP-ribosylates the a-subunits of G,‘s and G,, prevents pleckstrin phosphorylation by DIDS. 
N-Ethylmaleimide (SOpM), which uncouples G, from a,,-adrenoceptors, inhibits pleckstrin phosphorylation by DIDS in intact platelets. Activation 
of PKC by 55 nM phorbol 12-myristate 13-acetate and 500 nM platelet-activating factor are not disturbed by NEM. DIDS inhibits by 40 f 5% (n = 4) 
the pertussis toxin-catalyzed [“P]ADP-ribosylation of a 41 kDa protein fraction previously shown to contain the a-subunits of G,a-1, G,a-2 and G,a-3. 
Thus, the a,,-adrenergic receptor activates PKC via a G-protein of the G,-family. 
Key WV& a,-Adrenergic receptor; GTP-binding protein; Protein kinase C; Platelet 
1. Introduction 
Agonists such as a-thrombin, ADP and platelet-acti- 
vating factor (PAF) activate human platelets via phos- 
pholipase C (PLC)-dependent signal transduction. PLC 
cleaves phosphatidylinositol 4$biphosphate in inositol 
1,4,5_triphosphate (IP,) and SIZ 1 ,Zdiacylglycerol (DG), 
which respectively release intracellular Ca*’ ions [l] and 
activate protein kinase C (PKC) [2,3]. A second activat- 
ing pathway is mediated via phospholipase A, (PLA,) 
and formation of prostaglandin endoperoxides/throm- 
boxane A,, which induce platelet functions via a second- 
ary, PLC-mediated mechanism [4,5]. Subsequent reac- 
tions lead to the exposure of fibrinogen binding sites on 
the glycoprotein (GP) IIB/IIIA complex, aggregation 
and secretion of granule contents. 
Epinephrine induces platelet aggregation via activa- 
tion of PLA, independent of the PLC pathway, provided 
that secondary activation by prostaglandin endoperox- 
ides/thromboxane A, is prevented [4-61. Despite the ab- 
sence of DG formation there is evidence for increased 
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PKC activity, since the PKC inhibitor staurosporine pre- 
vents GP IIB/IIIA exposure by epinephrine [7-91. Also 
phosphorylation of the PKC substrate pleckstrin is en- 
hanced by epinephrine independent of formation of DG 
or phosphatidic acid [8,9]. These findings suggest, that 
the a,,-adrenergic receptor (a,,-AR) activates PKC via 
a mechanism that does not depend on DG formation. 
Sage et al. [lo] showed, that 4,4’-diisothiocyanato-stil- 
bene-2,2’-disulfonic acid (DIDS, 100 ,uM), an inhibitor 
of Cl-/HCO; exchange [l 1,121, increased the cytosolic 
pH in platelets, although platelets lack a Cl-/HCO; ex- 
changer. Previously Periasamy et al. [ 131 that DIDS in- 
teracts with the Q-AR on human platelets. Recently we 
described that at much lower concentrations (2-20 ,uM) 
of DIDS also enhance Na’/H’ exchange, but also acti- 
vates PKC and induces fibrinogen binding to GP IIB/ 
IIIA all via a mechanism that was inhibited by the CQ*- 
AR antagonists oxymetazoline and yohimbine [ 141. 
These responses were initiated without accumulation of 
phosphatidic acid, cytosolic Ca*’ and cyclooxygenase 
products, suggesting that PLC and PLA, were not in- 
volved. In contrast, the PKC inhibitor staurosporine in- 
hibited Na’/H’ exchange, exposure of GP IIB/IIIA and 
aggregation, indicating that activation of PKC was an 
early step in signal generation by the [DIDSI-[a,,-AR] 
complex. 
Many receptors trigger signal processing via hetero- 
trimeric G-proteins [15,16]. In the present study we in- 
vestigated whether G-proteins formed a link between the 
a,,-AR and PKC during platelet activation by DIDS. 
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2. Materials and methods 
2.1. Materials 
Staurosporine, guanosine-5’-O-(2-thiophosphate) GDP@)S), nicotin- 
amide adenine dinucleottde (NAD) and PAF were derived from 
Boehringer (Mannheim, Germany) and Sepharose 2B from Pharrnacia 
(Uppsala, Sweden). Alpha-thrombin, 4,4’-diisothiocyanatostilbene- 
2.~-disulfoni~ acid (DIDS), phorbol-12-my~state-13-a~tate (PMA), 
~-ethylmaleimide (NEM), ATP, indometha~ine, thymidine and pertus- 
sis toxin were from Sigma (St. Louis, MO, USA). [“PlOrthophosphate 
(snec.act. 8500-9120 Ciimmol) and ~2Plnicotinamide adenine dinucleo- 
L . . 
tide di(triethylammonium)salt ([“PINAD; spec.act. 800 Wmmol) were 
derived from New England Nuclear (Boston, MA, USA). Fibrinogen 
(grade L) was obtained from KABl (Stockholm, Sweden) and saponin 
from BDH Chemicals LTD (Poole, UK). All other chemicals were of 
analytical grade. 
3. Results 
Freshly drawn venous blood from healthy volunteers was collected 
(with informed consent) into tri-sodium citrate (0.1 vol. of 130 mM). 
The donors claimed not to have taken any medication during the 
previous ten days. 
2 3 Measurement of PKC actiwty 
Citrated blood was centrifuged (200 x g, 10 min, 22°C) and the plate- 
let rich plasma (PRP) was collected and acidified to pH 6.5 with 116 vol 
of ACD (2.5 g tri-sodium citrate, 1.5 g citric acid,.2.0 g o-glucose in 
100 ml water). Platelets were labelled with 0.1 mCi l’2Plortho- 
phosphate/ml acidified PRP (pH 6.5) in the presence of inddmefhacine 
(30 PM) for 1 h at 37°C. The platelets were isolated by centrifugation 
(700 x g, 15 min, 22°C) and resuspended in HEPES-Tyrode buffer (145 
mM NaCl, 5 mM KCI, 0.5 mM Na,PO,, 1 mM MgSO,. 10 mM HEPES 
pH 7.2) resulting in a final platelet count of (150-200) x 103@1. La- 
belled platelets were stimulated at 37’C. In several experiments perme- 
abilizeh platelets were used. After centrifugation, the-3’P-loaded plate- 
lets were resusnended in a buffer containing 160 mM KCI. 2.3 mM 
MgCIZ, 12 mM_HEPES, 10 mM thymidine, 0.15 mM ATP, 0.5 mM NAD 
and pertussis toxin (4 @ml). Platelets were pe~eabiii~d by saponin 
(20 #g/ml) added 2 min before addition of agonists. Samples were 
collected at the times indicated in section 3 and transferred into 0.5 vol 
of 3x concentrated Laemmli sample buffer and heated for 2 min at 
100°C prior to electrophoresrs. Proteins were separated by electropho- 
resis through a 11% polyacrylamide gel, according to Laemmli [17]. 
Gels were stained with Coomassie brilliant blue and the distribution of 
radioactivtty was determined by autoradiography of dried gels on 
Kodak Royal X-Omat film. For determinatton of the radioactivity of 
pleckstrm, the specific area was cut out of the dried gels and heated for 
2 h at 8O“C m 30% HZO,. The radioactivity was determined by liquid 
scintillation counting. Data are expressed as percentage of the maximal 
phosphorylation of pleckstrin induced by 1 min stimulation with a- 
thrombin (I U/ml) to minimize donor variation. 
2.4 (-‘-‘PjADP ribosylation by pertussis toxin 
PRP was acidified with ACD to pH 6.5 and platelets were isolated 
by centrifugation (700 x g, 15 min, 20°C). The platelet pellet was resus- 
nended in HEPES-Tvrode buffer (DH 7.2). to a final platelet count of 
800 x lo?@. Platelets were stimu&ted for 5 min at 3O’C before the 
addition of 3 vols. of ~bosylation buffer. containing pertussis toxin 
(13 &ml). [32P]NAD (67 JIM), saponin (20 fig/ml), 160 mM KCl. 27 
mM HEPES, 5 mM MgC1, and 13 PM EGTA. After 1 h incubation 
at 30°C. the permeabilized platelets were collected by centrifugation 
(12,000 x g, 30 s. 22°C) and solubilized in three times concentrated 
Laemmli sample buffer and heated for 5 min at 100°C. Protems were 
separated by electrophoresis through a 11% polyacrylamide gel and the 
radtoactivtty in the 41 kDa protein was determined, as described in 
section 2.3. Data are expressed as percentage inhibition of the amount 
of [“P]ADP ribosylation in unstimulated platelets. 
2.5. Presentatron of data 
Data are expressed as means It SD., unless indicated otherwise. Sta- 
tistical significances were determined by Student’s t-test and were con- 
sidered significant at P < 0.05. All experiments were performed with 
3-5 different platelet preparations. 
3.1. Effect of GDP(p)S on DIDS-induced pleckstrin 
phosphorylution 
Addition of DIDS (20 yM, final con.) to platelets 
induced a 4- to 5-fold increase in ‘UP-labelled pleckstrin, 
illustrating activation of PKC (Fig. lf. The a,,-receptor 
antagonist oxymetazohne [ 181 abolished the increase in 
[32P]pleckstrin completely, indicating that DIDS acti- 
vated PKC via the a,,-AR. A similar inhibition of PKC 
activation by DIDS was obtained following a 2 min pre- 
incubation with GDP(B)S (200 PM), provided that the 
platelets were made permeable with saponin [Is]. Con- 
trol studies confirmed that in the absence of platelet 
activators saponin did not change pleckstrin phosphoryl- 
ation (data not shown). On the other hand, a combina- 
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Fig. 1. Effect of GDP~)S on DIDS-induced pleckstrin phospho~la- 
tion. The upper figure shows 32P-labeled platelets pre-incubated with 
buffer (n), 500 PM oxymetazoline (o), 200 PM GDP@)S (0) or 
GDP(p)S in combination with 20 yM saponin (0) for 2 min at 
37°C. Subsequently, platelets were stimulated with DIDS (20pM). The 
radioactivity in pleckstrin was measured at different times after stimu- 
lation. The phosphorylation data are expressed as percentage of the 
maximal a-thrombm (I U/ml)-induced increase in pleckstrin phospho- 
rylation. The 47 kDa spots show the DIDS-induced increase in pleck- 
strin phosphorylation in the presence of GDP(#?)S (upper panel) or 
GDP(B)S in the presence of saponin (lower panel) at different times 
after addition of agonist. The tower figure shows pleckstrin phosphoryl- 
ation after strmulation with cc-thrombin (0.1 U/ml) in the presence of 
GDP(j?)S (200 PM) with (m) or without (o) preincubation with saponin 
(20 pglml). 
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tion of saponin and GDP@)S also prevented the increase 
in [32P] pleckstrin by a-thrombin (0.1 U/ml), confirming 
earlier observations that thrombin activates PKC via a 
G-protein-dependent pathway [20]. These findings indi- 
cate that the activation of PKC of DIDS depends on 
G-proteins. 
3.2. Effect of NEM on DIDS-induced pleckstrin 
phosphorylation 
NEM alkylates cysteine residues of the a-subunit of G, 
and uncouples G,a-2 from the a,,-AR [15,21-241. Fig. 
2A shows that the increase in [32P]pleckstrin duced by 
DIDS was completely inhibited after a 1 min preincuba- 
tion with 50 PM NEM. Unstimulated platelets showed 
no change in 32P-radioactivity in pleckstrin during treat- 
ment with NEM (data not shown). To investigate which 
step in the activation by DIDS was sensitive to NEM, the 
experiments were repeated during direct stimulation of 
PKC. As shown in Fig. 2B, NEM did not affect pleck- 
strin phosphorylation induced by 55 nM PMA, indicat- 
ing that the NEM sensitive step seen during stimulation 
by DIDS was not at the level of PKC activation. Further- 
more, the NEM sensitivity appeared specific for a,,-AR- 
mediated activation of PKC, since phosphorylation of 
pleckstrin induced by 500 nM PAF (Fig. 2C) and 1 U/ml 
a-thrombin (data not shown) was not sensitive to NEM 
treatment. Together these data suggest, that one or more 
G-proteins of the G,-family take part in the activation of 
PKC by the [a,,-AR]-[DIDS] complex. 
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A second means to demonstrate the involvement of 
G-proteins of the G,-family is by analyzing ADP-ribosyl- 
ation by pertussis toxin [24]. This toxin catalyzes the 
transfer of an ADP-ribose moiety, derived from NAD’, 
to a cysteine-residue of the a-subunit of G, [25], thereby 
blocking signal transduction. As also shown in Fig. 2A, 
preincubation of saponin-treated platelets with pertussis 
toxin inhibited pleckstrin phosphorylation by DIDS 
completely, illustrating that activation of PKC by DIDS 
is mediated by a G-protein of the G,-class. 
3.3. [32P]ADP ribosylation in platelets treated with 
DIDS 
To demonstrate the pertussis toxin sensitivity of 
DIDS-induced PKC activation in more detail, we deter- 
mined the effect of DIDS on [32P]ADP ribosylation of a,. 
Pertussis toxin ribosylates the unstimulated, intact 
heterotrimeric G-protein, whereas the liberated aGDp 
subunit is no longer susceptible to ADP-ribosylation 
[22,24]. As shown in Fig. 3 (lane 1). [32P]NAD-labelled 
platelets showed a considerable incorporation of the 
t 
Fig. 2. Effect of NEM and pertussis toxin on pleckstrin phosphoryla- 
tion induced by DIDS. (A) “P-labeled platelets preincubated with 
buffer (0) or with 50 PM NEM (0) for 2 min at 37’C. Subsequently, 
platelets were stimulated with DIDS (20pM). Alternatively, j2P-labeled 
platelets were preincubated with saponin (2O&ml) and pertussis toxin 
(4 .&/ml) for 2 min at 37°C before addition of 20 PM DIDS (8). The 
radioactivity in pleckstrin was measured at different times after stimu- 
lation. The phosphorylation data are expressed as percentage of maxi- 
mal a-thrombin (1 U/ml) induced increase in pleckstrin phosphoryla- 
tion. (B) “P-labeled platelets timulated with PMA (55 nM) without (A) 
or after a 2-min preincubation with 50 ,LLM NEM (A). (C) 32P- labeled 
platelets timulated with PAF (500 nM) without (0) or after a 2-min 
preincubation with 50 PM NEM (+). 
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Fig. 3. Effect of DIDS on pertussis toxin catalyzed [32P]ADP-ribosyla- 
tion. Platelets (800 x 103/pl) were stimulated with a-thrombin (1 U/ml) 
or DIDS (20 PM) for 5 min at 30°C. The stimulated platelets were 
diluted in 3 ~01s. of ribosylation buffer, containing pertussis toxin 
(13,~@ml), saponin (2Opg/ml) and [“PINAD (67pM). Following a l-h 
Incubation at 3O”C, the [32P]ADP-ribosylation was measured. The left 
panel shows a representative autoradiogram of unstimulated platelets 
(lane 1) and platelets stimulated with cc-thrombin (1 U/ml; lane 2). 
DIDS (20 PM; lane 3) or epinephrine (10 PM; lane 4). The right panel 
summarizes the data from 3 different experiments. The data are ex- 
pressed as percentage inhibition of the [“P]ADP-ribosylation measured 
in unstimulated platelets (means + S.D.; n = 3). 
32P-label in a 41 kDa protein, previously shown to con- 
tain different forms of ai [26]. Addition of a-thrombin 
(1 U/ml) reduced the ADP-ribosylation by 51 ? 12% 
(n = 3; lane 2). Addition of DIDS (20 PM) reduced the 
ADP-ribosylation by 40 ? 5% (n = 3; lane 3). Also epineph- 
rine, the natural agonist for the a,,-adrenergic receptor, 
inhibited ADP-ribosylation, although less potently than 
DIDS (lane 4). These data indicates, that DIDS activates 
a G protein, which is ADP-ribosylated by pertussis toxin. 
4. Discussion 
In a previous study we showed that DIDS activates 
platelets via the a,,-AR [14]. This activation was medi- 
ated by PKC and resulted in activation of the Na’/H’ 
exchanger, exposure of fibrinogen binding sites on the 
GP IIb/IIIa complex and aggregation. The present study 
indicates that activation of PKC by the [a,,-AR]-[DIDS] 
complex depends on one or more G-proteins of the G, 
family. Evidence for this concept comes from the obser- 
vation that the phosphorylation of pleckstrin is inhibited 
by GDP@)S, NEM, and pertussis toxin, and that DIDS 
inhibits [32P]ADP ribosylation of a 41 kDa protein con- 
sisting of the a, subtypes 1, 2 and 3 [26]. 
Human platelets are a prototypic tissue for the a,,- 
AR. The receptor contains seven transmembrane span- 
ning domains characteristic for G protein-coupled recep- 
tors [ 181. The a,,-AR is coupled to Gp-2, which is sensi- 
tive to pertussis-toxin [21,26]. Antibodies directed 
against he C-terminal part of this G-protein blocked the 
a,,-AR-induced inhibition of adenylyl cyclase, indicat- 
ing that activation of G,a-2 is a crucial step in this path- 
way [ 151. The a,,-AR expressed in LLC-PKl-O-cells 
couples not only to G,a-2 but also to G,a-1 and G,a-3 
[27]. Both G,a-a and G,a-3 are present in platelets [26], 
but at present it is unknown whether these G,‘s are acti- 
vated by the a,,-AR. When in fibroblasts both G,a-2 and 
G,a-3 were activated via the a,,-AR, only G,a-2 medi- 
ated inhibition of adenylyl cyclase and it is possible that 
also in platelets G,a-2 is more important than the other 
subtypes [28]. 
The a-subunits of G,a-1, G,a-2 and G,a-3 are highly 
conserved and have more than 90% amino acid sequence 
homology [29]. One of the conserved amino acids is a 
C-terminal cysteine located at position 351 or 352, which 
is a substrate for pertussis toxin [22,24,29]. The Sl sub- 
unit of this toxin is an ADP-ribosyltransferase, that cat- 
alyzes the transfer the ADP-ribose moiety of NAD’ to 
this C-terminal cysteine [25]. The same cystein is al- 
kylated by NEM [22,24], which disrupts its interaction 
with pertussis toxin [22]. Modification of this cysteine 
uncouples the G-protein from the activated receptor, 
abolishes signal generation and lowers the affinity of the 
receptor for its agonists. The affinity of the a,,-AR for 
[3H]UK 14,304 was about 30% lower after 30 min incu- 
bation with 100 PM NEM [30]. 
Both the inhibition of AC [31,32] and activation of 
PKC (this study) via the a,,-AR are abolished by pertus- 
sis toxin. A similar inhibition is seen with NEM ([23], this 
study), leading to complete blockade of a,,-AR-induced 
GTPase activity [33]. In platelets activated via the throm- 
bin receptor a different mechanism appears to be in- 
volved. Again the inhibition of AC [33] and activation 
of PKC [3 1.321 are abolished by pertussis toxin but NEM 
only prevents the inhibition of AC ([33], this study). In 
line with this observation is the 30% inhibition by NEM 
of a-thrombin induced GTPase activity [33]. By analogy 
with the a,,-AR, the thrombin receptor may inhibit AC 
via G,a-2. This a-subtype contains a second cysteine at 
position 112. Alkylation of this cysteine left the GTP- 
binding site intact [22], but prevented reassociation of the 
a-subunit with the P-complex [24]. The activation of 
PKC by a-thrombin must then be mediated via another 
G-protein of the G,-family with a lower sensitivity to 
NEM. G,a-1 and G,a-3 might be less sensitive to NEM 
since they lack the extra cysteine of G,a-2. 
Recently, Pan et al. [34] showed activation of a 
phosphotyrosine phosphatase from a human pancreatic 
cell line by a pertussis-toxin sensitive G-protein. Our 
present findings indicate that a serine/threonine kinase 
activity is regulated by G-proteins. Thus, phosphoryla- 
tion (this study) as well as dephosphorylation [34] may 
be under direct control of G-proteins. 
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